Allogene Therapeutics Inc
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| – | – | -7.2% | +71.1% | -14.4% | -21.8% | -21.8% | -14.6% | -24.2% | |
| – | – | +16.4% | +55.2% | -44.2% | +12.2% | -13.2% | -33.9% | -15.0% | |
| – | – | -75.7% | +4.7% | -5.5% | -64.3% | +34.3% | -9.5% | -31.3% | |
| – | – | -26.5% | +56.1% | -44.8% | +13.1% | -13.3% | -34.8% | -14.5% | |
| – | – | -22.7% | +16.5% | +114.3% | -45.0% | -48.5% | +11.8% | -21.1% | |
| – | – | – | – | – | – | – | – | – | |
| – | – | +142.6% | +17.7% | +3.5% | +59.7% | – | – | – | |
| – | – | -80.0% | – | – | – | – | – | – | |
| – | +3,534,450.0% | +25.6% | +66.9% | -15.2% | +23.1% | -15.6% | -3.1% | -2.5% | |
| – | +1,472,850.0% | +12.3% | +185.1% | -49.2% | +12.2% | -31.0% | -4.2% | -8.5% | |
| – | – | – | +77.1% | +7.6% | +87.6% | +12.9% | +10.8% | +9.3% | |
| – | – | -25.0% | +12.3% | -1.3% | +35.4% | -57.5% | -8.5% | -20.8% | |
| – | – | – | – | – | – | – | – | – | |
| – | – | -10.5% | +71.6% | -14.3% | -27.9% | -23.2% | -17.6% | -30.7% | |
| – | – | – | – | – | – | – | – | – | |
| – | +103.8% | +12.7% | +19.1% | +12.8% | +5.4% | +9.6% | +24.1% | +13.2% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.